JP2011502997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502997A5 JP2011502997A5 JP2010532292A JP2010532292A JP2011502997A5 JP 2011502997 A5 JP2011502997 A5 JP 2011502997A5 JP 2010532292 A JP2010532292 A JP 2010532292A JP 2010532292 A JP2010532292 A JP 2010532292A JP 2011502997 A5 JP2011502997 A5 JP 2011502997A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vitamin
- hydroxybenzoyl
- amino
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 19
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 19
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 10
- 229960002446 octanoic acid Drugs 0.000 claims 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000003086 colorant Substances 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98489807P | 2007-11-02 | 2007-11-02 | |
| US60/984,898 | 2007-11-02 | ||
| US2010808P | 2008-01-09 | 2008-01-09 | |
| US61/020,108 | 2008-01-09 | ||
| US8356608P | 2008-07-25 | 2008-07-25 | |
| US61/083,566 | 2008-07-25 | ||
| PCT/US2008/082064 WO2009059188A1 (en) | 2007-11-02 | 2008-10-31 | Method of treating vitamin b12 deficiency |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011502997A JP2011502997A (ja) | 2011-01-27 |
| JP2011502997A5 true JP2011502997A5 (enExample) | 2011-12-15 |
| JP5555634B2 JP5555634B2 (ja) | 2014-07-23 |
Family
ID=40591491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532292A Expired - Fee Related JP5555634B2 (ja) | 2007-11-02 | 2008-10-31 | ビタミンｂ１２欠乏症を治療するための方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8022048B2 (enExample) |
| EP (1) | EP2215047B1 (enExample) |
| JP (1) | JP5555634B2 (enExample) |
| KR (1) | KR101344369B1 (enExample) |
| CN (1) | CN101952241B (enExample) |
| AU (1) | AU2008318423B2 (enExample) |
| BR (1) | BRPI0817396C8 (enExample) |
| CA (1) | CA2704780C (enExample) |
| CL (1) | CL2010000434A1 (enExample) |
| CO (1) | CO6280475A2 (enExample) |
| DK (1) | DK2215047T3 (enExample) |
| ES (1) | ES2443817T3 (enExample) |
| MX (1) | MX2010004716A (enExample) |
| NZ (1) | NZ585080A (enExample) |
| PL (1) | PL2215047T3 (enExample) |
| PT (1) | PT2215047E (enExample) |
| RU (1) | RU2469728C2 (enExample) |
| WO (1) | WO2009059188A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110039930A1 (en) * | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| EP2538945A4 (en) * | 2010-02-24 | 2013-07-24 | Emisphere Tech Inc | Oral b12 therapy |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| US8805208B2 (en) * | 2012-02-03 | 2014-08-12 | Tyco Electronics Subsea Communications Llc | System and method for polarization de-multiplexing in a coherent optical receiver |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| HUE064694T2 (hu) | 2012-03-22 | 2024-04-28 | Novo Nordisk As | Továbbítószert tartalmazó készítmények és elõállításuk |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| US9603812B2 (en) | 2013-04-11 | 2017-03-28 | Richard Louis Price | Treatment of autistic spectrum disorder |
| US9211284B2 (en) | 2013-04-11 | 2015-12-15 | Richard Louis Price | Diagnosis and treatment of P.R.I.C.E. syndrome |
| US20170348417A1 (en) | 2013-04-11 | 2017-12-07 | Richard Louis Price | Treatment of attention deficit disorders and associated symptoms |
| US10098848B2 (en) | 2013-04-11 | 2018-10-16 | Richard Louis Price | Inositol-containing comestible units and methods of treatment using the same |
| US20140309270A1 (en) | 2013-04-11 | 2014-10-16 | Richard Louis Price | Diagnosis and treatment of a form of autistic spectrum disorder |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| CN109069475B (zh) | 2016-04-22 | 2022-01-28 | 受体控股公司 | 快速作用植物类医药化合物和营养补剂 |
| EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| AR113750A1 (es) * | 2017-10-05 | 2020-06-10 | Receptor Holdings Inc | Composiciones de hierbas con mejor biodisponibilidad |
| EA202090890A1 (ru) * | 2017-10-05 | 2020-09-03 | Ресептор Холдингз, Инк. | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| US12303487B2 (en) | 2018-11-19 | 2025-05-20 | Spoke Sciences, Inc. | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6274564B1 (en) * | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU771728B2 (en) * | 1998-12-28 | 2004-04-01 | Ya Global Investments, Lp | Cyanocobalamin (vitamin B12) treatment in allergic disease |
| EP1535625B1 (en) | 1999-04-05 | 2014-01-08 | Novartis AG | Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| JP4799794B2 (ja) * | 2000-03-21 | 2011-10-26 | エミスフェアー・テクノロジーズ・インク | ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。 |
| US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| JP5073153B2 (ja) | 2001-06-01 | 2012-11-14 | ノバルティス アーゲー | 副甲状腺ホルモンおよびカルシトニンの経口投与 |
| DE60233803D1 (de) | 2001-08-17 | 2009-11-05 | Novartis Ag | 5-cnac zur oralen verabreichung von parathormonfragmenten |
| US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TW200403052A (en) | 2002-07-17 | 2004-03-01 | Novartis Ag | Use of organic compounds |
| AR040737A1 (es) | 2002-08-01 | 2005-04-20 | Novartis Ag | Administracion oral de calcitonina |
| MXPA05002728A (es) * | 2002-09-13 | 2005-07-25 | Cydex Inc | Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada. |
| EP1611084A1 (en) | 2003-04-04 | 2006-01-04 | DSM IP Assets B.V. | Process for the manufacture of n-alkoxalyl-alaninates |
| US6938439B2 (en) | 2003-05-22 | 2005-09-06 | Cool Clean Technologies, Inc. | System for use of land fills and recyclable materials |
| JP3924616B2 (ja) | 2003-06-30 | 2007-06-06 | 独立行政法人物質・材料研究機構 | 微小サイズの温度感知素子を用いる温度計測方法 |
| JP2007525472A (ja) | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| MXPA06000446A (es) * | 2003-07-11 | 2006-04-07 | Novartis Ag | Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada. |
| PT2316473E (pt) | 2003-07-23 | 2013-09-20 | Novartis Ag | Utilização de calcitonina na osteoartrite |
| JP4903690B2 (ja) * | 2004-05-06 | 2012-03-28 | エミスフェアー・テクノロジーズ・インク | Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体 |
| US20060024241A1 (en) * | 2004-08-02 | 2006-02-02 | Bebaas, Inc. | Vitamin B12 compositions |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| US20060116334A1 (en) * | 2004-12-01 | 2006-06-01 | Curt Hendrix | Folate based composition for treatment of the cardiovascular system |
| GB0427603D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0427600D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| CA2626029A1 (en) * | 2005-11-04 | 2007-05-18 | Genta Incorporated | Pharmaceutical gallium compositions and methods |
-
2008
- 2008-10-31 US US12/262,677 patent/US8022048B2/en not_active Expired - Fee Related
- 2008-10-31 WO PCT/US2008/082064 patent/WO2009059188A1/en not_active Ceased
- 2008-10-31 AU AU2008318423A patent/AU2008318423B2/en not_active Ceased
- 2008-10-31 CA CA2704780A patent/CA2704780C/en not_active Expired - Fee Related
- 2008-10-31 CN CN200880119724.0A patent/CN101952241B/zh not_active Expired - Fee Related
- 2008-10-31 DK DK08844673.7T patent/DK2215047T3/da active
- 2008-10-31 NZ NZ585080A patent/NZ585080A/en not_active IP Right Cessation
- 2008-10-31 PL PL08844673T patent/PL2215047T3/pl unknown
- 2008-10-31 MX MX2010004716A patent/MX2010004716A/es active IP Right Grant
- 2008-10-31 BR BRPI0817396A patent/BRPI0817396C8/pt not_active IP Right Cessation
- 2008-10-31 ES ES08844673.7T patent/ES2443817T3/es active Active
- 2008-10-31 KR KR1020107010771A patent/KR101344369B1/ko not_active Expired - Fee Related
- 2008-10-31 JP JP2010532292A patent/JP5555634B2/ja not_active Expired - Fee Related
- 2008-10-31 PT PT88446737T patent/PT2215047E/pt unknown
- 2008-10-31 RU RU2010118423/15A patent/RU2469728C2/ru active
- 2008-10-31 EP EP08844673.7A patent/EP2215047B1/en not_active Not-in-force
-
2010
- 2010-04-30 CL CL2010000434A patent/CL2010000434A1/es unknown
- 2010-06-02 CO CO10066425A patent/CO6280475A2/es active IP Right Grant
-
2011
- 2011-08-09 US US13/206,090 patent/US8288360B2/en not_active Expired - Fee Related
-
2012
- 2012-09-14 US US13/618,654 patent/US8557792B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8969400B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
| WO2022035911A2 (en) | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent | |
| JP2013501717A5 (enExample) | ||
| JP5788527B2 (ja) | キナーゼ阻害剤の副作用低減剤 | |
| JP2016534153A5 (enExample) | ||
| JP2013542246A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2013522229A5 (enExample) | ||
| CN112654357B (zh) | 用于治疗非酒精性脂肪性肝炎的组合物和方法 | |
| NZ703564A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| JP2011026348A5 (enExample) | ||
| JP2013509395A5 (enExample) | ||
| JP2015500285A5 (enExample) | ||
| JP2012502047A5 (enExample) | ||
| JP2009513713A5 (enExample) | ||
| JP2012502103A5 (enExample) | ||
| JP2009102248A (ja) | 血中尿酸を急速に低減させるための医薬組成物およびパッケージならびに血中尿酸を急速に低減させるためのアンセリンの使用 | |
| JP2010138170A (ja) | 抗疲労組成物 | |
| MXPA04012462A (es) | Composicion medicinal solida estable para la administracion oral. | |
| JP2009517411A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| ES2763437T3 (es) | Composición para el tratamiento de la esterilidad | |
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| US20180140570A1 (en) | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof | |
| JP5776355B2 (ja) | 内服液剤 |